quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Applied Materials AMAT Q1 2026 Earnings Transcript

View original at nasdaq.com
Applied Materials AMAT Q1 2026 Earnings Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 4:30 p.m…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Metrology and inspection are growing as process complexity increases, with e-beam and optical platforms gaining traction

    80% confidence
  • Applied Materials delivered solid results in Q1 2026, driven by strong demand across AI, foundry-logic, and memory

    80% confidence
  • Applied Materials is well positioned for gate-all-around and backside power transitions with broad suite of solutions

    80% confidence
  • Company has seen some timing shifts typical for the industry, but no material cancellations; overall demand signals remain constructive

    80% confidence
  • In Q1 2026, Applied Materials delivered strong revenue, margins, and cash flow

    80% confidence
  • Company is seeing strong pull for tools supporting HBM, including patterning, dielectric deposition, and advanced packaging steps like hybrid bonding and TSV-related processes

    80% confidence
  • ICAPS demand remains healthy, supporting power, automotive, and industrial applications, though growth is moderating from peak levels

    80% confidence
  • EUV scaling increases requirements for patterning adjacencies, hard mask engineering, clean, and metrology/inspection

    80% confidence
  • Services mix continues to shift toward performance-based contracts

    80% confidence
  • R&D priorities include gate-all-around, backside power, advanced packaging, EUV adjacencies, new materials for scaling, and expanding metrology/inspection capabilities with AI-driven analytics

    80% confidence
  • OpEx will grow at a measured pace focused on R&D and customer enablement, with discipline on overhead

    80% confidence
  • Customers continue to accelerate node migrations and new 3D scaling approaches, expanding opportunity for differentiated materials engineering portfolio

    80% confidence
  • Both DRAM and NAND segments expected to grow through the year, with DRAM outpacing NAND near term

    80% confidence
  • Capital allocation priorities remain: invest in business for long-term growth, maintain strong balance sheet, and return excess cash through buybacks and dividends

    80% confidence
  • AI demand remains robust and broad-based, supporting sustained WFE strength with continued investment in leading-edge foundry-logic and advanced packaging

    80% confidence
  • Company continues to expand capacity in critical product lines and investing in supply resiliency, with lead times improving

    80% confidence
  • Services growth is supported by expanding installed base, higher attachment to performance-based agreements, and analytics-driven optimization

    80% confidence
  • Gate-all-around and backside power introduce new materials and integration challenges where company's leadership in materials engineering is a key differentiator

    80% confidence
  • Global footprint and broad portfolio allow supporting customers across regions within the regulatory framework

    80% confidence
  • Company has made progress diversifying suppliers, increasing dual-sourcing, and localizing critical components

    80% confidence
  • DRAM WFE is leading the recovery, particularly with HBM-driven investments, while NAND is improving at a slower pace

    80% confidence
  • Company is focused on operational discipline and supply chain execution to meet customer demand while advancing technology leadership

    80% confidence
  • Integrated solutions help customers improve line-edge roughness, CD control, and defectivity, critical as EUV moves deeper into HVM and to higher NA

    80% confidence
  • Backlog remains elevated with a book-to-bill around unity; working through backlog as supply improves

    80% confidence
  • Foundry-logic remains healthy with strength at leading nodes, while memory is improving, led by DRAM and HBM-related investments

    80% confidence
  • Visibility for HBM-related tools extends through multiple quarters given customers' capacity plans

    80% confidence
  • Applied Materials differentiates with a comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology

    80% confidence
  • Gross margin will reflect product and customer mix, as well as continued improvements in productivity and cost, expected to trend favorably as mix normalizes and cost actions take hold

    80% confidence
  • Services margins are stable to improving, supported by higher attachment, software content, and productivity initiatives

    80% confidence
  • Company continues to comply with all regulations; demand in China remains mixed by segment, with mature nodes steady and certain leading-edge areas impacted by restrictions

    80% confidence

Data points we hold from this source

Applied Materials, Inc. · book to bill ratio1.0 ratio
Applied Materials, Inc. · backlogelevated qualitative
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com